Citi Upgrades Acorda Therapeutics, Inc. (ACOR) to Buy
Tweet
Share
E-mailGet Alerts ACOR Hot Sheet
Price: $0.66 --0%
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
4 Buy, 12 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
Citi upgraded Acorda Therapeutics, Inc. (NASDAQ: ACOR) from Neutral to Buy with a price target of $33.00.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $25.17 yesterday.
For an analyst ratings summary and ratings history on Acorda Therapeutics, Inc. click here. For more ratings news on Acorda Therapeutics, Inc. click here.
Shares of Acorda Therapeutics, Inc. closed at $25.17 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Rothschild Redburn Upgrades Equifax (EFX) to Buy
- BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
